Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares

Rocket Pharmaceuticals' CEO, Gaurav Shah, recently divested $7,752 worth of the company's shares on August 18, 2026. The CEO sold 2,293 shares at a price of $3.381 each, fulfilling tax withholding requirements tied to the vesting of Restricted Stock Units (RSUs). These RSUs convert to common stock on a one-for-one basis. Current market prices for Rocket Pharmaceuticals' shares stand at $3.48, reflecting a 38% increase since their 52-week low of $2.53.

Despite trading below its 52-week high of $5.45, InvestingPro analysis suggests the company is undervalued at present. Following this sale, Shah retains a direct ownership of 1,056,594 shares, supplemented by 207,897 shares held by his spouse and 198,341 shares owned by the Gaurav D. Shah Irrevocable Trust. Rocket Pharmaceuticals demonstrates a robust current ratio of 9.24 and maintains more cash than debt on its balance sheet, although the company is rapidly depleting its cash reserves.

Investors can delve deeper into the company's financial metrics through additional ProTips available on the platform. Recently, Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million to the FDA, following the approval of its gene therapy for severe leukocyte adhesion deficiency-I. At the company's 2026 Annual Meeting of Stockholders, 74.02% of outstanding common shares were represented, with shareholders approving the election of seven new directors, including Peter Fong, M.D., and Mikael Dolsten, M.D., Ph.D.

In analyst reports, TD Cowen has assigned a Hold rating to Rocket Pharmaceuticals, noting safety concerns following a clinical hold on the company's RP-A501 gene therapy for Danon disease. TD Cowen's Tara Bancroft emphasized that safety remains the primary concern after the clinical hold. As Rocket Pharmaceuticals progresses in its gene therapy initiatives, these factors contribute to the company's ongoing strategy.